Dale Cooke, a consultant on pharmaceutical regulation and a 3L, was quoted in an Oct. 12 article in Politico about the Trump administration’s proposal for reducing drug prices.

An administration plan to require drug companies to include pricing information in consumer ads as a means to cut costs may have little effect, said Cooke, the founder of PhillyCooke Consulting, which provides consulting and training to ensure that promotional tactics comply with regulations of the Food and Drug Administration.

“The price of a drug has absolutely no relation to the cost for a consumer,” Cooke said, adding that a list price could frighten patients into thinking a medication is beyond their means, even if it’s covered by their insurance. “That would potentially be tragic.”

The article notes that the administration plan, which has faced strong opposition from the pharmaceutical industry and skepticism from independent experts, is expected to published in the Federal Register in October.

In the meantime, Cooke has discussed FDA regulations at recent and upcoming conferences, including AdvaMed’s MedTech Conference in Philadelphia on Sept. 26, the Regulatory Affairs Professional Society Convergence in Vancouver, British Columbia on Oct. 4 and the Food and Drug Law Institute Conference in Washington, D.C. on Oct. 16-17.